Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Can-Fite BioPharma ( (CANF) ) has provided an update.
On February 5, 2025, Can-Fite BioPharma Ltd. announced its participation in the BIO CEO & Investor Conference in New York City from February 10-11, 2025. The company plans to present the anti-obesity effects of Namodenoson, a key drug candidate. This event will also provide an opportunity for Can-Fite to discuss its business strategy and recent clinical milestones with investors and potential partners. The announcement reinforces Can-Fite’s commitment to expanding its influence in the biotechnology sector, particularly in addressing unmet medical needs in oncology and metabolic disorders.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs targeting oncological, metabolic, and inflammatory diseases. The company is advancing Namodenoson, a drug candidate in Phase III trials for liver cancer and Phase IIb for MASH, as well as Piclidenoson for psoriasis, among others.
YTD Price Performance: -22.35%
Average Trading Volume: 463,007
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $15.17M
See more insights into CANF stock on TipRanks’ Stock Analysis page.
